Key result
An E-PASS comprehensive risk score ≥0.5 was an independent risk factor for mortality from comorbid disease in patients surgically treated for gastric cancer (P=0.022).
Why the study?
Does the E-PASS comprehensive risk score predict postsurgical mortality from comorbid disease in elderly gastric cancer patients?
Cohort (n=414)
Does the E-PASS comprehensive risk score predict postsurgical mortality from comorbid disease in elderly gastric cancer patients?
p-value: p=0.022
The E-PASS-based comprehensive risk score is a useful predictor of comorbidity-related mortality in elderly patients undergoing surgery for gastric cancer.
E-PASS ≥0.5 may flag higher comorbidity mortality risk after gastric cancer surgery; leaves open its role in guiding decisions for elderly patients.
BACKGROUND AND OBJECTIVES: The long-term prognosis of elderly gastric cancer patients is poor because of the cancer and unrelated comorbidities. We investigated the risk factors for mortality after gastrectomy to aid surgeons in deciding the correct operative procedure for elderly gastric cancer patients. METHODS: A total of 414 gastric cancer patients surgically treated between 2002 and 2012 were divided into two groups A (≥75 years) and B (<75 years). Data were collected retrospectively and analyzed using the Estimation of Physiological Ability and Surgical Stress (E-PASS) scoring system as a predictor of postoperative complications. RESULTS: Overall survival (P < 0.001), disease-specific survival (P = 0.029), and survival rate related to comorbid disease (P < 0.001) were significantly reduced in elderly patients compared with younger patients. Surgical treatment for Group A involved lesser extent of nodal resection (P < 0.001). Multivariate analysis revealed that a comprehensive risk score (CRS) ≥0.5 based on the E-PASS score (P = 0.022) and severe postoperative complication (P = 0.002) were independent risk factors for mortality from comorbid disease. CONCLUSIONS: Thus, E-PASS-based CRS was a good predictor of comorbidity-related mortality. CRS may help surgeons select elderly patients with gastric cancer for surgical or other therapies.
No takes yet. Share an insight, caveat, or question.
Ariake et al. (2013) conducted a cohort in gastric cancer (n=414). E-PASS comprehensive risk score (CRS) ≥0.5 vs. CRS <0.5 was evaluated on mortality from comorbid disease (p=0.022). An E-PASS comprehensive risk score ≥0.5 was an independent risk factor for mortality from comorbid disease in patients surgically treated for gastric cancer (P=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: